Valuation: VISEN Pharmaceuticals

Market Cap 1.87B 2.17B 276M 239M 223M 205M 387M 26.28B 392M 2.62B 1.03B 13.15B 1.04B 1.02B 43.54B P/E 2026 *
-18.2x
P/E 2027 * -30.6x
Enterprise Value 1.6B 1.86B 237M 206M 192M 176M 333M 22.58B 337M 2.25B 884M 11.3B 892M 872M 37.42B EV / Sales 2026 *
23.7x
EV / Sales 2027 * 4.17x
Free-Float
26.93%
Yield 2026 *
-
Yield 2027 * -
1 day-1.81%
1 week-0.15%
Current month+1.35%
1 month-14.83%
3 months-21.92%
6 months-42.59%
Current year-40.49%
1 week 19.09
Extreme 19.09
20
1 month 18.5
Extreme 18.5
22.6
Current year 18.5
Extreme 18.5
43.3
1 year 18.5
Extreme 18.5
50.6
3 years 18.5
Extreme 18.5
69.15
5 years 18.5
Extreme 18.5
69.15
10 years 18.5
Extreme 18.5
69.15
Manager TitleAgeSince
Chief Executive Officer 60 07/11/2018
Director of Finance/CFO 42 13/10/2025
Chief Tech/Sci/R&D Officer 54 01/04/2020
Director TitleAgeSince
Director/Board Member 60 07/11/2018
Director/Board Member 44 08/01/2021
Director/Board Member 60 01/04/2021
Date Insider Type Main position Quantity % Market Cap.
1/1/26 A Other

Chief Executive Officer

108,750 0.0955%
Change 5-day change 1-year change 3-year change Capi.($)
-1.81%-0.15%-58.68% - 276M
+0.80%-2.33%+0.68%+13.87% 48.57B
+1.98%+9.05%+413.94%+532.17% 41.95B
+3.44%-4.65%+28.34%+8.81% 38.85B
+1.40%+0.10%+6.61%+61.93% 37.24B
+2.42%+5.72%+12.38%+44.79% 30.67B
-0.16%-3.11% - - 16.1B
+2.20%+0.48%+34.71%+127.15% 16.41B
+0.86%+2.16%+8.48%+19.35% 13.97B
+4.25%-8.23%-1.49%-35.46% 12.62B
Average +1.51%-0.73%+49.44%+96.58% 25.66B
Weighted average by Cap. +1.87%-0.12%+82.21%+120.40%

Financials

2026 *2027 *
Net sales 67.73M 78.7M 10.03M 8.69M 8.1M 7.45M 14.06M 954M 14.22M 95.19M 37.36M 477M 37.68M 36.85M 1.58B 447M 520M 66.27M 57.4M 53.5M 49.21M 92.9M 6.3B 93.94M 629M 247M 3.15B 249M 243M 10.44B
Net income -99M -115M -14.66M -12.7M -11.84M -10.89M -20.56M -1.39B -20.79M -139M -54.6M -698M -55.08M -53.86M -2.31B -58M -67.39M -8.59M -7.44M -6.94M -6.38M -12.04M -817M -12.18M -81.51M -31.99M -409M -32.27M -31.55M -1.35B
Net Debt -262M -305M -38.85M -33.65M -31.37M -28.85M -54.47M -3.69B -55.08M -369M -145M -1.85B -146M -143M -6.12B 486K 565K 72K 62.36K 58.13K 53.46K 101K 6.85M 102K 683K 268K 3.43M 270K 264K 11.34M
Logo VISEN Pharmaceuticals
Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.
Employees
-
Date Price Change Volume
06/08/26 HK$19.52 -1.81% 1,400
05/08/26 HK$19.88 -0.35% 2,100
04/08/26 HK$19.95 +0.30% 7,700
03/08/26 HK$19.89 +3.27% 2,300
31/07/26 HK$19.26 -1.48% 9,800
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17.11CNY
Average target price
44.50CNY
Spread / Average Target
+160.05%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2561 Stock